Kaleido Biosciences (KLDO) Financial Statements
Kaleido Biosciences Financial Overview
Kaleido Biosciences's market cap is currently $4.26K. The company's EPS TTM is $-1.71; its P/E ratio is 0.00; Kaleido Biosciences is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 21 | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.10M | $ 975.00K | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -1.25M | $ -54.99M | $ -1.32M | $ 0.00 | $ 0.00 |
| Operating Income | $ -87.67M | $ -78.87M | $ -86.66M | $ -60.68M | $ -27.03M |
| EBITDA | $ -85.09M | $ -77.00M | $ -84.04M | $ -59.03M | $ -26.70M |
| Net Income | $ -90.29M | $ -81.62M | $ -85.01M | $ -61.74M | $ -27.56M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 38.47M | $ 46.22M | $ 71.24M | $ 76.09M | $ 28.46M |
| Total Assets | $ 50.14M | $ 59.34M | $ 82.31M | $ 85.33M | $ 30.75M |
| Total Debt | $ 21.69M | $ 21.01M | $ 20.46M | $ 14.92M | $ 14.91M |
| Net Debt | $ -16.78M | $ -25.21M | $ -50.78M | $ -61.16M | $ -13.54M |
| Total Liabilities | $ 39.53M | $ 38.85M | $ 33.42M | $ 27.13M | $ 74.43M |
| Stockholders' Equity | $ 10.61M | $ 20.50M | $ 48.88M | $ 58.20M | $ -43.68M |
| Cash Flow | |||||
| Free Cash Flow | $ -78.22M | $ -65.54M | $ -79.38M | $ -49.32M | $ -23.90M |
| Operating Cash Flow | $ -77.09M | $ -61.52M | $ -75.80M | $ -46.32M | $ -22.50M |
| Investing Cash Flow | $ -691.00K | $ -4.02M | $ -3.59M | $ -3.00M | $ -1.41M |
| Financing Cash Flow | $ 70.04M | $ 40.40M | $ 74.64M | $ 98.91M | $ 49.74M |
Currency in USD